OTC: ACXIF 21.95%
Underperform Recommendation Issued On ACXIF By RBC Capital
NASDAQ: NGNE 31.15%
Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy
NYSE: KORE 77.39%
KORE Reports Third Quarter 2025 Results
NASDAQ: PRAA 32.17%
PRA Group (PRAA) Q4 2025 Earnings Call Transcript
NASDAQ: PSKY 24.52%
Warner Bros Discovery Deal: Why Netflix May Have Still Won
NYSE: DELL 21.57%
Why Dell Stock Surged Today
NYSE: ACXIF 31.15%
NYSE: NGNE 31.15%
NYSE: KORE 31.15%
NYSE: PRAA 31.15%
NYSE: PSKY 31.15%
